Loomis, Sayles & Company
SCLN

Loomis, Sayles & Company’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Loomis, Sayles & Company’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-828
Closed -$8K – 1161
2016
Q3 		$8K Buy
828
+408
+97% +$4.44K ﹤0.01% 813
2016
Q2 		$5K Buy
+420
New +$5.5K ﹤0.01% 868

Other funds holding SCLN

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Loomis, Sayles & Company's SCLN Position: Q4 2016 in Review

Loomis, Sayles & Company sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2016, closing a stake of 828 shares — an estimated $8K sold.

Loomis, Sayles & Company first reported a position in SCLN in Q2 2016 and held it in 2 quarters. The position peaked at $8K in Q3 2016. 153 funds tracked by Wall St. Rank hold SCLN as of Q4 2016.

  • Loomis, Sayles & Company reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2016 after selling out during the quarter.
  • Loomis, Sayles & Company sold 828 Sciclone Pharmaceuticals Inc shares in Q4 2016, an estimated $8K.
  • Loomis, Sayles & Company first reported a position in Sciclone Pharmaceuticals Inc in Q2 2016 and held it in 2 quarters.
  • Loomis, Sayles & Company's Sciclone Pharmaceuticals Inc position peaked at $8K in Q3 2016.
  • 153 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2016.

Based on Loomis, Sayles & Company's 13F filing for Q4 2016, filed 14 Feb 2017.